Study design and methods: U.S. study to protect brain health through lifestyle intervention to reduce risk (U.S. POINTER).

INTRODUCTION: The U.S. study to protect brain health through lifestyle intervention to reduce risk (U.S. POINTER) is conducted to confirm and expand the results of the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) in Americans. METHODS: U.S. POINTER was planned as a 2-year randomized controlled trial of two lifestyle interventions in 2000 older adults at risk for dementia due to well-established factors. The primary outcome is a global cognition composite that permits harmonization with FINGER. RESULTS: U.S. POINTER is centrally coordinated and conducted at five clinical sites (ClinicalTrials.gov: NCT03688126). Outcomes assessments are completed at baseline and every 6 months. Both interventions focus on exercise, diet, cognitive/social stimulation, and cardiovascular health, but differ in intensity and accountability. The study partners with a worldwide network of similar trials for harmonization of methods and data sharing. DISCUSSION: U.S. POINTER is testing a potentially sustainable intervention to support brain health and Alzheimer's prevention for Americans. Impact is strengthened by the targeted participant diversity and expanded scientific scope through ancillary studies.

Chondrosarcoma of the larynx and review of the literature.

Chondrosarcoma (CS) of the larynx was first described in 1935. Cartilaginous tumours of the larynx are largely rare and there is little literature concerning them. Laryngeal CS manifest with a different pathological behaviour to other malignancies of the larynx and as such the treatment of these neoplasias are different. The purpose of this review is to present a detailed report of the laryngeal CS in recent literature. We present a case of laryngeal CS of the cricoid cartilage and a case of a sarcomatous neoplasm of the vocal cord as a potential differential diagnosis. Although representing a rare malignancy, the last decade has brought new insights in surgical treatment of laryngeal CS and subsequent reduction in recurrence rates, whereas progress in tumour biology and etiological agents is still scarce. We concentrate on new insights in classification, radiologic and pathologic features, and treatment modalities in the last two decades. Based on the literary evidence the authors recommend a conservative laryngeal function-preserving surgery. Total laryngectomy should be reserved to recurrent CS and rare cases of voluminous high-grade CS of the larynx.

A three-step purification method of large quantities of human recombinant alpha endothelial cellular growth factor for clinical use.

The endothelial cellular growth factor alpha-ECGF is a candidate drug for the induction of therapeutic neoangiogenesis. Its use in extensive experimental and clinical trials is hampered by the fact that currently published purification procedures allow only small yields, and the absence of pyrogenic impurities is not demonstrated. The rh alpha-ECGF was expressed in E. coli. Isolation of rh alpha-ECGF from E. coli lysates to apparent homogenicity was achieved by a three step purification procedure involving ionic exchange, heparin-sepharose and polymyxin B chromatography. By this method, 200 mg of rh alpha-ECGF was purified from 15 g wet weight E. coli bacteria. The isolated protein of 18 kDa appeared as a single band after SDS gel electrophoresis and subsequent silver-staining. The biological activity was expressed in the chorion-allantois-membrane assay and in the 3H-thymidine proliferation in baby hamster kidney cells. Drug trials with rabbits revealed no increase in body temperature after intravenous injections with 1 mg rh-ECGF.